CL2013003484A1 - Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. - Google Patents
Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras.Info
- Publication number
- CL2013003484A1 CL2013003484A1 CL2013003484A CL2013003484A CL2013003484A1 CL 2013003484 A1 CL2013003484 A1 CL 2013003484A1 CL 2013003484 A CL2013003484 A CL 2013003484A CL 2013003484 A CL2013003484 A CL 2013003484A CL 2013003484 A1 CL2013003484 A1 CL 2013003484A1
- Authority
- CL
- Chile
- Prior art keywords
- phenyl
- carboxamide
- pyrazole
- taar1
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
COMPUESTOS DERIVADOS DE N-(4-MORFOLIN-2-II)FENIL)-1H-PIRAZOL-(3 O 5)-CARBOXAMIDA O N-(4-PIPERIDIN-3-IL)FENIL)- 1H-PIRAZOL-(3 O 5)-CARBOXAMIDA DE FÓRMULA: AFINES A RECEPTORES ASOCIADOS A TAAR1; PROCEDIMIENTO DE PREPARACIÓN; COMPOSICIÓN FARMACÉUTICA Y USO EN EL TRATAMIENTO Y/O LA PROFILAXIS DE ENFERMEDADES TALES COMO DEPRESIÓN, TRASTORNO BIPOLAR, ALZHEIMER Y PARKINSON, ENTRE OTRAS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11169217 | 2011-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013003484A1 true CL2013003484A1 (es) | 2014-08-08 |
Family
ID=46298390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013003484A CL2013003484A1 (es) | 2011-06-09 | 2013-12-05 | Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. |
Country Status (32)
Country | Link |
---|---|
US (1) | US9073911B2 (es) |
EP (1) | EP2717873B1 (es) |
JP (1) | JP5914642B2 (es) |
KR (1) | KR101574905B1 (es) |
CN (1) | CN103596567B (es) |
AR (1) | AR088741A1 (es) |
AU (1) | AU2012266457B2 (es) |
BR (1) | BR112013031324B1 (es) |
CA (1) | CA2837255C (es) |
CL (1) | CL2013003484A1 (es) |
CO (1) | CO6801764A2 (es) |
CY (1) | CY1116778T1 (es) |
DK (1) | DK2717873T3 (es) |
EA (1) | EA024648B1 (es) |
EC (1) | ECSP13013072A (es) |
ES (1) | ES2546438T3 (es) |
HK (1) | HK1191862A1 (es) |
HR (1) | HRP20151077T1 (es) |
IL (1) | IL229549B (es) |
MA (1) | MA35192B1 (es) |
MX (1) | MX347239B (es) |
MY (1) | MY162160A (es) |
PE (1) | PE20140934A1 (es) |
PL (1) | PL2717873T3 (es) |
PT (1) | PT2717873E (es) |
RS (1) | RS54183B1 (es) |
SG (1) | SG195156A1 (es) |
SI (1) | SI2717873T1 (es) |
TW (1) | TWI440636B (es) |
UA (1) | UA110525C2 (es) |
WO (1) | WO2012168260A1 (es) |
ZA (1) | ZA201308939B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
US9181230B2 (en) | 2012-01-12 | 2015-11-10 | Hoffmann-La Roche Inc. | Morpholine compounds and uses thereof |
HUE037689T2 (hu) | 2012-09-14 | 2018-09-28 | Hoffmann La Roche | Pirazol-karboxamid származékok mint TAAR-modulátorok különféle rendellenességek, mint például depresszió, cukorbetegség és Parkinson-kór kezelésében történõ alkalmazásra |
EP2928473B1 (en) * | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
MY195528A (en) | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
TWI783993B (zh) | 2017-04-24 | 2022-11-21 | 美商提薩羅有限公司 | 尼拉帕尼(niraparib)之製備方法 |
CN109748873B (zh) * | 2017-11-08 | 2021-02-02 | 北京嘉林药业股份有限公司 | 化合物及其治疗癌症的用途 |
ES2966457T3 (es) * | 2018-06-18 | 2024-04-22 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de MALT1 |
KR102161787B1 (ko) * | 2018-07-02 | 2020-10-06 | 한국기초과학지원연구원 | 수면 장애의 예방 또는 치료용 약학적 조성물 |
WO2020064792A1 (en) | 2018-09-27 | 2020-04-02 | F. Hoffmann-La Roche Ag | Heterocyclyl compounds for the treatment of autoimmune disease |
WO2020175957A1 (ko) * | 2019-02-28 | 2020-09-03 | 주식회사 마더스제약 | 피라졸 아마이드 유도체 화합물 및 이의 용도 |
JP2022532718A (ja) * | 2019-05-14 | 2022-07-19 | メタボメッド リミテッド | Acss2阻害剤およびその使用方法 |
WO2023283369A1 (en) * | 2021-07-08 | 2023-01-12 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
WO2023183444A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
WO2024033459A1 (en) * | 2022-08-12 | 2024-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
IL136388A0 (en) | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
KR101335845B1 (ko) | 2007-02-15 | 2013-12-02 | 에프. 호프만-라 로슈 아게 | Taar1 리간드로서의 2-아미노옥사졸린 |
US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
US9132136B2 (en) * | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
US9029370B2 (en) * | 2011-06-10 | 2015-05-12 | Hoffmann-La Roche Inc. | Substituted benzamide derivatives |
CN102899314A (zh) | 2011-07-29 | 2013-01-30 | 江汉大学 | 一种批量基因克隆的方法 |
-
2012
- 2012-06-01 US US13/485,969 patent/US9073911B2/en active Active
- 2012-06-06 ES ES12727632.7T patent/ES2546438T3/es active Active
- 2012-06-06 PL PL12727632T patent/PL2717873T3/pl unknown
- 2012-06-06 WO PCT/EP2012/060627 patent/WO2012168260A1/en active Application Filing
- 2012-06-06 PE PE2013002748A patent/PE20140934A1/es active IP Right Grant
- 2012-06-06 MY MYPI2013004400A patent/MY162160A/en unknown
- 2012-06-06 CN CN201280027873.0A patent/CN103596567B/zh active Active
- 2012-06-06 KR KR1020147000462A patent/KR101574905B1/ko active IP Right Grant
- 2012-06-06 UA UAA201400123A patent/UA110525C2/ru unknown
- 2012-06-06 JP JP2014514042A patent/JP5914642B2/ja active Active
- 2012-06-06 EP EP12727632.7A patent/EP2717873B1/en active Active
- 2012-06-06 TW TW101120350A patent/TWI440636B/zh active
- 2012-06-06 BR BR112013031324-2A patent/BR112013031324B1/pt active IP Right Grant
- 2012-06-06 AU AU2012266457A patent/AU2012266457B2/en active Active
- 2012-06-06 DK DK12727632.7T patent/DK2717873T3/en active
- 2012-06-06 PT PT127276327T patent/PT2717873E/pt unknown
- 2012-06-06 RS RS20150549A patent/RS54183B1/en unknown
- 2012-06-06 EA EA201391787A patent/EA024648B1/ru not_active IP Right Cessation
- 2012-06-06 SI SI201230279T patent/SI2717873T1/sl unknown
- 2012-06-06 MX MX2013013853A patent/MX347239B/es active IP Right Grant
- 2012-06-06 CA CA2837255A patent/CA2837255C/en active Active
- 2012-06-06 SG SG2013087234A patent/SG195156A1/en unknown
- 2012-06-07 AR ARP120102009A patent/AR088741A1/es unknown
-
2013
- 2013-10-31 CO CO13258855A patent/CO6801764A2/es active IP Right Grant
- 2013-11-21 IL IL229549A patent/IL229549B/en active IP Right Grant
- 2013-11-27 ZA ZA2013/08939A patent/ZA201308939B/en unknown
- 2013-12-05 CL CL2013003484A patent/CL2013003484A1/es unknown
- 2013-12-09 EC ECSP13013072 patent/ECSP13013072A/es unknown
- 2013-12-18 MA MA36583A patent/MA35192B1/fr unknown
-
2014
- 2014-05-30 HK HK14105124.2A patent/HK1191862A1/zh unknown
-
2015
- 2015-10-06 CY CY20151100893T patent/CY1116778T1/el unknown
- 2015-10-12 HR HRP20151077TT patent/HRP20151077T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013003484A1 (es) | Compuestos derivados de n-(4-morfolin-2-il)fenil)-1h-pirazol-(3 o 5)-carboxamida o n-(4-piperidin-3-il)fenil)-1h-pirazol-(3 o 5)-carboxamida afines a receptores asociados a taar1; procedimiento de preparacion; composicion farmaceutica y uso en el tratamiento y/o la profilaxis de enfermedades tales como depresion, trastorno bipolar, alzheimer y parkinson, entre otras. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
CL2010001159A1 (es) | Compuestos derivados de 3,8-diazabiciclo[2.4.0]octano y 3,6-diazabiciclo[3.2.0]heptano disustituidos, moduladores del receptor de orexina; composicion farmaceutica; utiles en el tratamiento de trastornos del sueño, trastornos metabolicos, entre otros. | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
CL2013002474A1 (es) | Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras. | |
IN2014DN09434A (es) | ||
PH12015500746A1 (en) | Benzamides | |
NI201500142A (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos. | |
MX2017004950A (es) | Composiciones y metodos para tratar el insomnio. | |
CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
CL2008002268A1 (es) | Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros. | |
CL2008000434A1 (es) | Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros. | |
GB2511685A (en) | Muscarinic m1 receptor agonists | |
PH12015501339A1 (en) | Indole carboxamide derivatives as p2x7 receptor antagonists | |
EA201590873A1 (ru) | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов | |
GEP20196969B (en) | New therapeutical composition containing apomorphine as active ingredient | |
PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
CL2013002424A1 (es) | Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras. | |
UA117154C2 (uk) | Антагоністи s1p3 | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
GB201115977D0 (en) | Neurodevelopmental disorders |